HACKENSACK, N.J. and PETACH TIKVAH, Israel, Dec. 10, 2015 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has rescheduled its conference call, originally scheduled for Wednesday, December 16, 2015 to Monday, January 11, 2016, due to longer than expected embargo on one of the important items to be discussed on the call. Mr. Chaim Lebovits, BrainStorm's President and Chief Executive Officer will provide an update to shareholders and discuss important company developments.
Prof. Dimitrios Karussis, MD, PhD, of the department of Neurology at Hadassah Medical Center in Jerusalem, will also participate. Prof. Karussis serves as Principal Investigator in clinical trials conducted by the company in Israel.
Conference call details:
Monday, January 11, 2016 @ 10:45am ET / 7:45am PT
Replays, Available through January 25, 2016
A replay of the call and webcast will be available on the company's website: www.brainstorm-cell.com
About BrainStorm Cell Therapeutics Inc
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn® has been administered to over 60 patients with ALS in clinical trials conducted in Israel and the United States, and is currently being studied in a randomized, double-blind, placebo-controlled clinical trial at three major clinical centers in the United States. For more information, visit the Company's website at www.brainstorm-cell.com.
Safe Harbor Statement
Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. These forward-looking statements are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.
Chief Operating Officer
BRAINSTORM CELL THERAPEUTICS INC.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/brainstorm-reschedules-corporate-update-conference-call-to-january-11-2016-300191183.html
SOURCE BrainStorm Cell Therapeutics Inc.